BILL ANALYSIS

S864

BULLISH

HELP Copays Act

S864 (HELP Copays Act) has been assessed with a bullish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bullish

Market Sentiment

7/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

The HELP Copays Act would mandate counting manufacturer copay assistance toward patient deductibles and OOP max, boosting drug utilization.

Pharmaceutical companies (LLY, MRK, PFE, ABBV, JNJ) are primary beneficiaries with estimated 1-3% revenue uplift.

Health insurers (UNH) face increased drug claim costs, but the impact is mitigated by PBM capabilities and represents a small percentage of total revenue.

How S864 Affects the Market

The HELP Copays Act directly impacts healthcare sector dynamics. Pharmaceutical companies with strong branded drug portfolios (LLY, MRK, PFE, ABBV, JNJ) could see modest revenue gains if the bill passes, due to improved effectiveness of copay cards. Insurers like UNH may face higher medical costs but the impact is small relative to their scale. No market price data is available, but the structural bias is positive for pharma and slightly negative for insurers.

Bill Details

Metric	Value
Bill Number	S864
Market Sentiment	bullish
Event Date	March 19, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

The HELP Copays Act (S.864) would require group health plans to count financial assistance from drug manufacturers and non-profits toward patient deductible and out-of-pocket limits. The bill is in committee with 26 cosponsors and a companion House bill. If enacted, it would benefit pharmaceutical companies by boosting drug utilization, while insurers face higher claims costs. No market data is provided, but structural impacts are clear.

Full AI Market Analysis

The HELP Copays Act (S.864) was introduced on March 5, 2025 by Sen. Roger Marshall (R-KS) and has 26 cosponsors including both parties. Hearings were held in the Senate HELP Committee on March 19, 2026. The bill amends the Public Health Service Act to require that amounts paid by or on behalf of individuals—including financial assistance from non-profit organizations and prescription drug manufacturers—count toward the deductible, coinsurance, copayment, and out-of-pocket limit. A companion bill (HR6423) has been introduced in the House. The bill is still in committee and has not passed either chamber. The legislation involves no direct government funding; it is a regulatory mandate on private health insurance plans. The money trail runs through insurance claims: by counting manufacturer copay assistance toward out-of-pocket limits, patients will hit their deductibles and maximums faster, increasing insurer liability for drug costs. Pharmaceutical companies benefit because patients are more likely to fill prescriptions when copay assistance is effective, boosting sales volume. No convergence signals are present in the provided data. The bill stands alone as a targeted health policy initiative. Structural winners are pharmaceutical companies with high-priced branded drugs that use copay assistance programs: $LLY (revenue $34.1B), $MRK ($60.1B), $PFE ($59.6B), $ABBV ($54.3B), ($85.2B). For these, the bill enhances their existing patient assistance programs, potentially increasing net revenue by 1-3% depending on drug mix. Structural losers are health insurers: (revenue $371.6B) faces higher drug claim costs, though its Optum PBM may offset some impact through formulary adjustments. The net effect on UNH is bearish but moderate given its diversified business. Timeline: The bill has advanced from introduction to hearings, indicating active committee work. However, it has not yet passed the Senate. The next steps are committee markup and then a floor vote. The companion House bill adds momentum but passage this Congress is uncertain. Legislative velocity is moderate.